about
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesMHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue.Driving CAR T-cells forwardGenetics, genomics, and evolutionary biology of NKG2D ligands.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differentiaExpression and prognostic significance of unique ULBPs in pancreatic cancerThe Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.Exploiting natural killer group 2D receptors for CAR T-cell therapy.Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretionExosomes: From Functions in Host-Pathogen Interactions and Immunity to Diagnostic and Therapeutic Opportunities.Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.Natural killer group 2D and CD28 receptors differentially activate mammalian/mechanistic target of rapamycin to alter murine effector CD8+ T-cell differentiation.NKG2D ligand RAE1ε induces generation and enhances the inhibitor function of myeloid-derived suppressor cells in mice.Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism.Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer.Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid.Biological roles and potential applications of immune cell-derived extracellular vesicles.Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Prognostic value of MICA/B in cancers: a systematic review and meta-analysis.Innate immune cells for immunotherapy of autoimmune and cancer disorders.Sensing Bacterial-Induced DNA Damaging Effects via Natural Killer Group 2 Member D Immune Receptor: From Dysbiosis to Autoimmunity and Carcinogenesis.Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment.NKG2D and Its Ligands: "One for All, All for One".The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.Tumor immunotherapy: New aspects of natural killer cells.Selenium, Selenoproteins, and ImmunityNKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy
P2860
Q28074619-CBD3423C-AD36-49BB-A0C8-7CC00C39C5C8Q33639723-A2C74EA1-B3D1-4809-80F0-DB97B8F48011Q34046505-4D5898DA-C501-4633-9D31-2D75F3921B3FQ34489980-2A11105F-81EA-457D-BBD1-D56BF1DFA406Q35600095-8BF9C68E-BA6D-431D-AA29-C88E40286D7DQ35743162-09ECF070-7BFC-4026-B2D8-EA4C31B4BB9FQ37229770-AC1A6996-3D36-41E1-A04C-1CB7B36BEEC4Q38670431-393799E3-7179-4F72-99D1-D4C02A0706B8Q38671184-EAD94A90-9734-421F-9F8C-129EDF70F7A0Q38706890-3AEB667D-3B16-41E3-BD3F-02624088D7C7Q38947856-063BD87F-FC54-42AC-9752-146296FB0D8EQ38962024-9AC05810-2478-4B91-92C3-6FA11BD38639Q40217706-7E703CD6-94FB-4F59-B663-1153747F55B2Q40301456-1EC5D836-442D-40AA-B1C7-442096DD4FDEQ40399586-B4D0AD21-138D-4E53-B7C4-CDC2655956D2Q40436097-140665B2-2D33-4D10-BD8D-80F89D4B5816Q42511974-5FC85773-7DCA-4543-9822-1DC11FB93D89Q46193686-CBA477CB-64A9-494E-AEEF-1BE4DC5F7A56Q47156322-314F2A6C-84FE-4681-A645-8350B5D79EE2Q47162990-6051D32A-22B3-4BF6-A701-8EBE4EB90972Q48316500-5919B6F6-7684-4C95-8F01-3F67B0F588EEQ49221858-E99CE79F-E393-43FF-A0E5-4FA467A3F7ECQ52758918-AF48A405-96F0-4E2E-8C65-3EE0844248C5Q52780147-4E44A5A5-3365-441E-9AF1-BFC90E52C473Q54234609-B4D79665-41F3-4E91-A4C2-A81A0172C645Q55001650-EDACA96F-B828-4BB0-9127-2C9E8908CC11Q55107050-8F21134D-1212-41EF-941C-E1262061CEFCQ57255341-3703F445-3E45-4D66-8A61-B9B548EE9E93Q58750637-8878DF5F-99E2-4F43-B9BE-518800BA88AD
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
@ast
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
@en
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
@nl
type
label
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
@ast
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
@en
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
@nl
prefLabel
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
@ast
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
@en
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
@nl
P2093
P2860
P3181
P356
P1476
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
@en
P2093
Fahmin Basher
Jennifer D. Wu
Jinyu Zhang
P2860
P3181
P356
10.3389/FIMMU.2015.00097
P407
P577
2015-03-04T00:00:00Z